Levodropropizine Elc

Levodropropizine, the active ingredient in Levodropropizine Elc, is an antitussive presented as an oral formulation for oral use. It is used to suppress dry, non‑productive coughs in adults and children when appropriate.

GNH USA supplies Levodropropizine Elc as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality manufacturing, regulatory compliance, and reliable distribution across global markets. The company adheres to stringent quality standards and provides comprehensive support for product registration and logistics.

Levodropropizine is an oral peripheral antitussive used to manage coughs arising from irritation of the respiratory tract.

- Dry cough: reduces the frequency and intensity of cough episodes. - Non‑productive cough: helps relieve coughing without mucus production. - Upper respiratory tract irritation: alleviates cough caused by viral infections.

Levodropropizine is generally well tolerated, but some patients may experience adverse reactions.

Common Side Effects: - Nausea: mild stomach upset may occur. - Dizziness: transient light‑headedness reported. - Headache: occasional mild headache. - Taste alteration: temporary change in taste perception.

Serious or Rare Side Effects: - Allergic reaction: rash, itching, or swelling. - Hepatic disorder: elevated liver enzymes. - Anaphylaxis: severe, potentially life‑threatening hypersensitivity.

When using Levodropropizine, consider the following safety measures.

- Use in children: follow pediatric guidance and avoid use in infants under 2 years unless advised. - Renal impairment: adjust use or monitor if the patient has severe kidney disease. - Hepatic disease: exercise caution in patients with liver dysfunction. - Concomitant CNS depressants: monitor for additive sedation. - Store at ambient temperature: keep below 25°C, retain original packaging, and protect from moisture.

Levodropropizine may interact with other medicines; review the following categories.

Major Interactions (Avoid): - MAO inhibitors: risk of enhanced serotonergic effects. - Strong CYP450 inhibitors: may increase plasma concentrations of levodropropizine.

Moderate Interactions (Monitor Closely): - Antihistamines: may augment antitussive effect. - Opioid cough suppressants: additive central cough suppression not required. - Alcohol: may increase drowsiness.